Search results for "Benzhydryl Compound"

showing 10 items of 53 documents

Biomonitoring of bisphenols A, F, S and parabens in urine of breastfeeding mothers: Exposure and risk assessment

2019

In the present study we used human biomonitoring to assess the internal exposure and the risk to four parabens and three bisphenols in 103 Spanish breastfeeding mothers participating in the BETTERMIILK project. Urinary methylparaben (MP), ethylparaben (EP), propylparaben (PP) and butylparaben (BP) presented detection frequencies ranging from 12% (BP) to 92% (MP), while bisphenol A (BPA), bisphenol F (BPF) and bisphenol S (BPS) were detected in 76% (BPA) and 20% (BPF, BPS) of the mothers. Average paraben concentrations (geometric mean) ranged from 0.021 ng mL(-1) (BP) to 17.7 ng mL(-1) (MP), whereas bisphenols had geometric means concentrations from 0.042 ng mL(-1) (BPF) to 0.927 ng mL(-1) (…

PopulationMothersParabensContext (language use)BisphenolsUrineUrine010501 environmental sciencesRisk Assessment01 natural sciencesBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsHumansMedicine030212 general & internal medicineFood scienceBenzhydryl CompoundsEthylparabeneducation0105 earth and related environmental sciencesGeneral Environmental ScienceBreastfeeding mothersButylparabeneducation.field_of_studyMethylparabenbusiness.industryParabenBreast FeedingchemistryBisphenol SBiomonitoringFemalebusinessBiological MonitoringEnvironmental Research
researchProduct

Regulatory identification of BPA as an endocrine disruptor : Context and methodology

2018

International audience; BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies, the analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An ap…

0301 basic medicineendocrine systemBrain developmentpertubateur endocrinienEndocrine disruptionContext (language use)Computational biologyMESH: Social Control Formal010501 environmental sciencesBiologyEndocrine Disruptors01 natural sciencesBiochemistryMammary gland developmentbisphenol A;endocrine disruption;ED;SVHC;substance of very high concern;REACh03 medical and health sciencesEndocrinologyBisphenol AMESH: PhenolsPhenolsSubstance of very high concernMESH: Benzhydryl CompoundsFood and Nutritionbisphénol aAnimalsHumansBenzhydryl CompoundsMolecular BiologyComputingMilieux_MISCELLANEOUSSVHC0105 earth and related environmental sciencesEndocrinology and metabolismurogenital systemsubstance toxiqueED3. Good healthSocial Control FormalMESH: Endocrine Disruptors030104 developmental biologyEndocrine disruptor[SDV.TOX]Life Sciences [q-bio]/ToxicologyAlimentation et NutritionEndocrinologie et métabolismeREACHIdentification (biology)
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study a…

2017

Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of pa…

randomized controlled trial; real-life; retrospective study; sodium glucose co-transporter-2 inhibitor; medicine (miscellaneous); endocrinology; diabetes and metabolism; nutrition and dietetics; cardiology and cardiovascular medicineBlood GlucoseTime FactorsGlucosideGlycated Hemoglobin ATime FactorMedicine (miscellaneous)Settore MED/13 - EndocrinologiaEndocrinologyGlucosidesSodium-Glucose Transporter 2Retrospective StudieDiabetes MellitusHumansHypoglycemic AgentsData MiningBenzhydryl CompoundsRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSodium-Glucose Transporter 2 InhibitorsRetrospective StudiesGlycated HemoglobinBenzhydryl CompoundNutrition and DieteticsEvidence-Based MedicineHypoglycemic AgentSodium-Glucose Transporter 2 InhibitorRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based MedicineReal-lifeBiomarkerDiabetes and MetabolismRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineRetrospective studyTreatment OutcomeDiabetes Mellitus Type 2ItalyRandomized controlled trialResearch DesignSodium glucose co-transporter-2 inhibitorCrowdsourcingCardiology and Cardiovascular MedicineBiomarkersType 2Human
researchProduct

Multi-residue determination of 47 organic compounds in water, soil, sediment and fish—Turia River as case study

2017

A sensitive and reliable method based on solid-liquid extraction (SLE) using McIlvaine-Na2EDTA buffer (pH = 4.5)-methanol and solid-phase extraction (SPE) clean up prior to ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC–MS/MS) was applied to determine 47 organic contaminants in fish, soil and sediments. The SPE procedure to clean-up the extracts was also used as extraction method to determine these compounds in water. Recoveries ranged from 38 to 104% for all matrices with RSDs 50% for 36 compounds in front of 9, matrix effect < 20% for 31 compounds against 21, and LOQs <25 ng g−1 for 38 compounds against 22) indicates that the proposed method is mor…

Drugs of abuseGeologic SedimentsAcetonitrilesClinical BiochemistryPharmaceutical ScienceFresh WaterExtraction010501 environmental sciencesQuechersMass spectrometry01 natural sciencesHigh-performance liquid chromatographyAnalytical ChemistrySoilPhenolsRiversLC–MS/MSLimit of DetectionTandem Mass SpectrometryPlasticizersDrug DiscoveryAnimalsBenzhydryl CompoundsWater pollutionChromatography High Pressure LiquidSpectroscopy0105 earth and related environmental sciencesChromatographyChemistrySolid Phase Extraction010401 analytical chemistryExtraction (chemistry)FishesWaterSoil classificationSoil contamination0104 chemical sciencesPersonal care productsEnvironmental chemistryPharmaceuticalsWater qualityWater Pollutants Chemical
researchProduct

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

2020

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Me…

MaleIGA NEPHROPATHYRATIONALEPROGRESSIONType 2 diabetesurologic and male genital diseasesDiabetic nephropathychemistry.chemical_compoundGlucosidesDESIGNMedicineFAILUREDiabetic NephropathiesDapagliflozinrandomized controlled clinical trialPrognosisfemale genital diseases and pregnancy complications//purl.org/pe-repo/ocde/ford#3.02.13 [https]Cardiovascular DiseasesNephrologyFemalesodium–glucose co-transporter-2 inhibitormedicine.symptomBENAZEPRILGlomerular Filtration Ratemedicine.medical_specialtyFinerenoneINHIBITIONNephropathy//purl.org/pe-repo/ocde/ford#3.02.20 [https]Double-Blind MethodClinical ResearchInternal medicineDiabetes mellitusEND-POINTSHumansBenzhydryl CompoundsRenal Insufficiency ChronicAcademicSubjects/MED00340Sodium-Glucose Transporter 2 InhibitorsAgedTransplantationDECLINEbusiness.industrysodium-glucose co-transporter-2 inhibitordapagliflozinmedicine.diseaseEFFICACYEditor's ChoiceDiabetes Mellitus Type 2chemistryAlbuminuriaORIGINAL ARTICLESbusinesschronic kidney diseaseKidney disease
researchProduct

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Blood GlucoseMalemedicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabeteslcsh:Diseases of the endocrine glands. Clinical endocrinologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agents030212 general & internal medicineDapagliflozinBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinlcsh:RC648-665business.industryType 2 Diabetes Mellitusnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomechemistryDiabetes Mellitus Type 2Observational studyDrug Therapy CombinationFemalebusinessBody mass indexmedicine.drugResearch ArticleJournal of diabetes research
researchProduct

Bisphenol-A impairs insulin action and up-regulates inflammatory pathways in human subcutaneous adipocytes and 3T3-L1 cells.

2013

Current evidence indicates that chemical pollutants may interfere with the homeostatic control of nutrient metabolism, thereby contributing to the increased prevalence of metabolic disorders. Bisphenol-A (BPA) is a lipophilic compound contained in plastic which is considered a candidate for impairing energy and glucose metabolism. We have investigated the impact of low doses of BPA on adipocyte metabolic functions. Human adipocytes derived from subcutaneous adipose tissue and differentiated 3T3-L1 cells were incubated with BPA, in order to evaluate the effect on glucose utilization, insulin sensitivity and cytokine secretion. Treatment with 1 nM BPA significantly inhibited insulin-stimulate…

Leptinmedicine.medical_treatmentAdipose tissuechemistry.chemical_compoundMice0302 clinical medicineAdipocyteAdipocytesInsulinPhosphorylation0303 health sciencesMultidisciplinaryPERSISTENT ORGANIC POLLUTANTS BODY-MASS INDEX METABOLIC SYNDROME ENVIRONMENTAL CONTAMINANTS CARDIOVASCULAR-DISEASE ENDOCRINE DISRUPTORS SERUM CONCENTRATIONS WIDESPREAD EXPOSURE PERINATAL EXPOSURE DIABETES-MELLITUSbiologyQRNF-kappa BCell Differentiation3. Good healthUp-RegulationAdipogenesisMedicinehormones hormone substitutes and hormone antagonistsResearch ArticleSignal TransductionSTAT3 Transcription Factormedicine.medical_specialtyendocrine systemScienceSubcutaneous FatDown-Regulation030209 endocrinology & metabolism03 medical and health sciencesDownregulation and upregulationPhenolsInternal medicine3T3-L1 CellsmedicineAnimalsHumansRNA MessengerBenzhydryl Compounds030304 developmental biologyInflammationurogenital systemInsulinJNK Mitogen-Activated Protein KinasesReceptor InsulinInsulin receptorEndocrinologyGlucosechemistry13. Climate actionbiology.proteinCytokine secretionGLUT4PloS one
researchProduct

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprote…

2019

Objective: Abdominal aortic aneurysm (AAA) is a pathological condition of permanent vessel dilatation that predisposes to the potentially fatal consequence of aortic rupture. SGLT-2 (sodium-glucose cotransporter 2) inhibitors have emerged as powerful pharmacological tools for type 2 diabetes mellitus treatment. Beyond their glucose-lowering effects, recent studies have shown that SGLT-2 inhibitors reduce cardiovascular events and have beneficial effects on several vascular diseases such as atherosclerosis; however, the potential effects of SGLT-2 inhibition on AAA remain unknown. This study evaluates the effect of oral chronic treatment with empagliflozin—an SGLT-2 inhibitor—on dissecting …

0301 basic medicineDissecting Abdominal Aortic AneurysmApolipoprotein EMalemedicine.medical_specialtyInflammation030204 cardiovascular system & hematologyp38 Mitogen-Activated Protein Kinases03 medical and health sciencesMice0302 clinical medicineApolipoproteins EGlucosidesInternal medicinemedicineAnimalsHumansBenzhydryl CompoundsAortic ruptureSodium-Glucose Transporter 2 InhibitorsCells CulturedNeovascularization Pathologicbusiness.industryAngiotensin IINF-kappa Bmedicine.diseaseAngiotensin IIAbdominal aortic aneurysmMatrix MetalloproteinasesMice Inbred C57BLAortic Dissection030104 developmental biologyEndocrinologySodium/Glucose Cotransporter 2Knockout mousemedicine.symptomChemokinesCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalArteriosclerosis, thrombosis, and vascular biology
researchProduct

Genotoxic and endocrine activities of bis(hydroxyphenyl)methane (bisphenol F) and its derivatives in the HepG2 cell line

2008

International audience; Human can be exposed to bis(hydroxyphenyl)methane (bisphenol F or BPF) and its derivatives as environment and food's contaminants. This study was investigated to identify and to compare toxic potency of BPF, BFDGE, and two of BPF metabolites using in vitro methods. BPF did not induce any genic mutation in bacteria when the Ames test was performed according to the OECD guideline. In contrast, using Human cell lines and Comet assay, we demonstrated that BPF and Bisphenol F Diglycidyl Ether (BFDGE) were effective on HepG2 cell DNA fragmentation at non-cytotoxic concentrations. DHB was also positive but at higher concentrations, near its limit of solubility. Neither BPF,…

StereochemistryCell SurvivalEndocrine activitiesOxidative BPF metabolitesBisphenol F Diglycidyl Ether (BFDGE)[SDV.TOX.TCA]Life Sciences [q-bio]/Toxicology/Toxicology and food chain010501 environmental sciencesEndocrine DisruptorsToxicologymedicine.disease_causeTransfection01 natural sciencesAmes testCell Line03 medical and health scienceschemistry.chemical_compoundHuman cell linesmedicineHumansEstrogens Non-SteroidalBenzhydryl CompoundsBisphenol F (BPF)Bisphenol A diglycidyl ether030304 developmental biology0105 earth and related environmental sciences0303 health sciencesMicronucleus TestsMutagenicity TestsAndrogen AntagonistsMolecular biologyIn vitro3. Good healthComet assaychemistryCell cultureMicronucleus testDNA fragmentationComet AssayGenotoxicityGenotoxicityMutagens
researchProduct